Abstract
Intraductal papillary mucinous neoplasms (IPMN) of the pancreas are of increasing interest in the field of pancreatic surgery ever since their first description as an individual pancreatic tumor entity in 1982. The decision for surgical or conservative management is based on the adenoma-carcinoma sequence and the differentiation into main-duct or branch-duct IPMN. Invasive IPMN forms (carcinoma in situ and invasive carcinoma) and in particular noninvasive IPMNs (adenoma and borderline tumors) reveal significantly better survival rates than ductal adenocarcinoma of the pancreas.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma / mortality
-
Adenocarcinoma / pathology
-
Adenocarcinoma / surgery
-
Adenocarcinoma, Mucinous / diagnosis
-
Adenocarcinoma, Mucinous / mortality
-
Adenocarcinoma, Mucinous / pathology
-
Adenocarcinoma, Mucinous / surgery*
-
Carcinoma in Situ / diagnosis
-
Carcinoma in Situ / mortality
-
Carcinoma in Situ / pathology
-
Carcinoma in Situ / surgery
-
Carcinoma, Pancreatic Ductal / diagnosis
-
Carcinoma, Pancreatic Ductal / mortality
-
Carcinoma, Pancreatic Ductal / pathology
-
Carcinoma, Pancreatic Ductal / surgery*
-
Carcinoma, Papillary / diagnosis
-
Carcinoma, Papillary / mortality
-
Carcinoma, Papillary / pathology
-
Carcinoma, Papillary / surgery*
-
Humans
-
Magnetic Resonance Imaging
-
Neoplasm Invasiveness
-
Neoplasm Staging
-
Pancreas / pathology
-
Pancreatectomy / methods*
-
Pancreatic Neoplasms / diagnosis
-
Pancreatic Neoplasms / mortality
-
Pancreatic Neoplasms / pathology
-
Pancreatic Neoplasms / surgery*
-
Prognosis
-
Radiography, Dual-Energy Scanned Projection
-
Survival Rate
-
Tomography, Spiral Computed